The treatment of chronic depression, Part 2: A double-blind, randomized trial of sertraline and imipramine

Martin B. Keller, Alan J. Gelenberg, Robert M A Hirschfeld, A. John Rush, Michael E. Thase, James H. Kocsis, John C. Markowitz, Jan A. Fawcett, Lorrin M. Koran, Daniel N. Klein, James M. Russell, Susan G. Kornstein, James P. McCullough, Sonia M. Davis, Wilma M. Harrison

Research output: Contribution to journalArticle

160 Citations (Scopus)

Abstract

Background: Chronic depression appears to be a common, frequently disabling illness that is often inadequately treated. Unlike episodic depressions with shorter illness duration, neither acute nor long-term treatment approaches for chronic depression have been well studied. Method: 635 outpatients at 12 sites who met DSM-III-R criteria for chronic major depression or double depression were randomly assigned to 12 weeks of double- blind treatment with either sertraline tin daily doses of 50-200 mg) or imipramine (in daily doses of 50-300 mg). Efficacy and safety were assessed either weekly or every 2 weeks during the 12 weeks of acute treatment. Results: Despite high rates of chronicity (mean duration of major depression = 8.9 ± 9.1 years; mean duration of dysthymia = 23 ± 13 years) and high rates of comorbidity, 52% of patients achieved a satisfactory therapeutic response to sertraline or imipramine (by a conservative, intent-to-treat analysis). Approximately 21% of the patients who had achieved a therapeutic response at week 12 had not done so at week 8, confirming the longer time to response in depressions with high chronicity. Patients treated with sertraline reported significantly fewer adverse events and were significantly less likely to discontinue treatment due to side effects than imipramine- treated patients (6.3% vs. 12.0%). Conclusion: These results indicate that patients suffering from depression with high chronicity can achieve a good therapeutic response to acute treatment with either sertraline or imipramine, although sertraline is better tolerated.

Original languageEnglish (US)
Pages (from-to)598-607
Number of pages10
JournalJournal of Clinical Psychiatry
Volume59
Issue number11
StatePublished - Nov 1998

Fingerprint

Sertraline
Imipramine
Therapeutics
Tin
Diagnostic and Statistical Manual of Mental Disorders
Comorbidity
Outpatients
Safety

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Keller, M. B., Gelenberg, A. J., Hirschfeld, R. M. A., Rush, A. J., Thase, M. E., Kocsis, J. H., ... Harrison, W. M. (1998). The treatment of chronic depression, Part 2: A double-blind, randomized trial of sertraline and imipramine. Journal of Clinical Psychiatry, 59(11), 598-607.

The treatment of chronic depression, Part 2 : A double-blind, randomized trial of sertraline and imipramine. / Keller, Martin B.; Gelenberg, Alan J.; Hirschfeld, Robert M A; Rush, A. John; Thase, Michael E.; Kocsis, James H.; Markowitz, John C.; Fawcett, Jan A.; Koran, Lorrin M.; Klein, Daniel N.; Russell, James M.; Kornstein, Susan G.; McCullough, James P.; Davis, Sonia M.; Harrison, Wilma M.

In: Journal of Clinical Psychiatry, Vol. 59, No. 11, 11.1998, p. 598-607.

Research output: Contribution to journalArticle

Keller, MB, Gelenberg, AJ, Hirschfeld, RMA, Rush, AJ, Thase, ME, Kocsis, JH, Markowitz, JC, Fawcett, JA, Koran, LM, Klein, DN, Russell, JM, Kornstein, SG, McCullough, JP, Davis, SM & Harrison, WM 1998, 'The treatment of chronic depression, Part 2: A double-blind, randomized trial of sertraline and imipramine', Journal of Clinical Psychiatry, vol. 59, no. 11, pp. 598-607.
Keller MB, Gelenberg AJ, Hirschfeld RMA, Rush AJ, Thase ME, Kocsis JH et al. The treatment of chronic depression, Part 2: A double-blind, randomized trial of sertraline and imipramine. Journal of Clinical Psychiatry. 1998 Nov;59(11):598-607.
Keller, Martin B. ; Gelenberg, Alan J. ; Hirschfeld, Robert M A ; Rush, A. John ; Thase, Michael E. ; Kocsis, James H. ; Markowitz, John C. ; Fawcett, Jan A. ; Koran, Lorrin M. ; Klein, Daniel N. ; Russell, James M. ; Kornstein, Susan G. ; McCullough, James P. ; Davis, Sonia M. ; Harrison, Wilma M. / The treatment of chronic depression, Part 2 : A double-blind, randomized trial of sertraline and imipramine. In: Journal of Clinical Psychiatry. 1998 ; Vol. 59, No. 11. pp. 598-607.
@article{798ab96937bf4f73a9299eff2e21247b,
title = "The treatment of chronic depression, Part 2: A double-blind, randomized trial of sertraline and imipramine",
abstract = "Background: Chronic depression appears to be a common, frequently disabling illness that is often inadequately treated. Unlike episodic depressions with shorter illness duration, neither acute nor long-term treatment approaches for chronic depression have been well studied. Method: 635 outpatients at 12 sites who met DSM-III-R criteria for chronic major depression or double depression were randomly assigned to 12 weeks of double- blind treatment with either sertraline tin daily doses of 50-200 mg) or imipramine (in daily doses of 50-300 mg). Efficacy and safety were assessed either weekly or every 2 weeks during the 12 weeks of acute treatment. Results: Despite high rates of chronicity (mean duration of major depression = 8.9 ± 9.1 years; mean duration of dysthymia = 23 ± 13 years) and high rates of comorbidity, 52{\%} of patients achieved a satisfactory therapeutic response to sertraline or imipramine (by a conservative, intent-to-treat analysis). Approximately 21{\%} of the patients who had achieved a therapeutic response at week 12 had not done so at week 8, confirming the longer time to response in depressions with high chronicity. Patients treated with sertraline reported significantly fewer adverse events and were significantly less likely to discontinue treatment due to side effects than imipramine- treated patients (6.3{\%} vs. 12.0{\%}). Conclusion: These results indicate that patients suffering from depression with high chronicity can achieve a good therapeutic response to acute treatment with either sertraline or imipramine, although sertraline is better tolerated.",
author = "Keller, {Martin B.} and Gelenberg, {Alan J.} and Hirschfeld, {Robert M A} and Rush, {A. John} and Thase, {Michael E.} and Kocsis, {James H.} and Markowitz, {John C.} and Fawcett, {Jan A.} and Koran, {Lorrin M.} and Klein, {Daniel N.} and Russell, {James M.} and Kornstein, {Susan G.} and McCullough, {James P.} and Davis, {Sonia M.} and Harrison, {Wilma M.}",
year = "1998",
month = "11",
language = "English (US)",
volume = "59",
pages = "598--607",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "11",

}

TY - JOUR

T1 - The treatment of chronic depression, Part 2

T2 - A double-blind, randomized trial of sertraline and imipramine

AU - Keller, Martin B.

AU - Gelenberg, Alan J.

AU - Hirschfeld, Robert M A

AU - Rush, A. John

AU - Thase, Michael E.

AU - Kocsis, James H.

AU - Markowitz, John C.

AU - Fawcett, Jan A.

AU - Koran, Lorrin M.

AU - Klein, Daniel N.

AU - Russell, James M.

AU - Kornstein, Susan G.

AU - McCullough, James P.

AU - Davis, Sonia M.

AU - Harrison, Wilma M.

PY - 1998/11

Y1 - 1998/11

N2 - Background: Chronic depression appears to be a common, frequently disabling illness that is often inadequately treated. Unlike episodic depressions with shorter illness duration, neither acute nor long-term treatment approaches for chronic depression have been well studied. Method: 635 outpatients at 12 sites who met DSM-III-R criteria for chronic major depression or double depression were randomly assigned to 12 weeks of double- blind treatment with either sertraline tin daily doses of 50-200 mg) or imipramine (in daily doses of 50-300 mg). Efficacy and safety were assessed either weekly or every 2 weeks during the 12 weeks of acute treatment. Results: Despite high rates of chronicity (mean duration of major depression = 8.9 ± 9.1 years; mean duration of dysthymia = 23 ± 13 years) and high rates of comorbidity, 52% of patients achieved a satisfactory therapeutic response to sertraline or imipramine (by a conservative, intent-to-treat analysis). Approximately 21% of the patients who had achieved a therapeutic response at week 12 had not done so at week 8, confirming the longer time to response in depressions with high chronicity. Patients treated with sertraline reported significantly fewer adverse events and were significantly less likely to discontinue treatment due to side effects than imipramine- treated patients (6.3% vs. 12.0%). Conclusion: These results indicate that patients suffering from depression with high chronicity can achieve a good therapeutic response to acute treatment with either sertraline or imipramine, although sertraline is better tolerated.

AB - Background: Chronic depression appears to be a common, frequently disabling illness that is often inadequately treated. Unlike episodic depressions with shorter illness duration, neither acute nor long-term treatment approaches for chronic depression have been well studied. Method: 635 outpatients at 12 sites who met DSM-III-R criteria for chronic major depression or double depression were randomly assigned to 12 weeks of double- blind treatment with either sertraline tin daily doses of 50-200 mg) or imipramine (in daily doses of 50-300 mg). Efficacy and safety were assessed either weekly or every 2 weeks during the 12 weeks of acute treatment. Results: Despite high rates of chronicity (mean duration of major depression = 8.9 ± 9.1 years; mean duration of dysthymia = 23 ± 13 years) and high rates of comorbidity, 52% of patients achieved a satisfactory therapeutic response to sertraline or imipramine (by a conservative, intent-to-treat analysis). Approximately 21% of the patients who had achieved a therapeutic response at week 12 had not done so at week 8, confirming the longer time to response in depressions with high chronicity. Patients treated with sertraline reported significantly fewer adverse events and were significantly less likely to discontinue treatment due to side effects than imipramine- treated patients (6.3% vs. 12.0%). Conclusion: These results indicate that patients suffering from depression with high chronicity can achieve a good therapeutic response to acute treatment with either sertraline or imipramine, although sertraline is better tolerated.

UR - http://www.scopus.com/inward/record.url?scp=0031789697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031789697&partnerID=8YFLogxK

M3 - Article

C2 - 9862606

AN - SCOPUS:0031789697

VL - 59

SP - 598

EP - 607

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 11

ER -